AGTR1 and hepatocellular carcinoma: To investigate whether AGTR1 affected the therapeutic effect of sorafenib in HCC cells, AGTR1-overexpressed HepG2 and Huh7 cells (Figures 3A,B) were administrated with 8 μM sorafenib lasting 4 days.